New treatment options for patients with advanced neuroendocrine tumors (Q34173336)

31 July 2017

1 reference

title

New treatment options for patients with advanced neuroendocrine tumors (English)

1 reference

31 July 2017

Jennifer A Chan

1

1 reference

31 July 2017

Matthew H Kulke

series ordinal

2

1 reference

31 July 2017

publication date

1 June 2011

1 reference

Current Treatment Options in Oncology

31 July 2017

published in

1 reference

31 July 2017

volume

12

1 reference

31 July 2017

issue

2

1 reference

31 July 2017

page(s)

136-148

1 reference

One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0148-2

Hepatic surgery for metastases from neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0148-2

Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0148-2

Operative resection of primary carcinoid neoplasms in patients with liver metastases yields significantly better survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0148-2

Results of liver transplantation in the treatment of metastatic neuroendocrine tumors. A 31-case French multicentric report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0148-2

Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the M.D. Anderson experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0148-2

Permanent transarterial embolization of neuroendocrine metastases of the liver using cyanoacrylate and lipiodol: assessment of mid- and long-term results

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0148-2

The management of patients with advanced carcinoid tumors and islet cell carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0148-2

Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0148-2

Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0148-2

Peptide receptor radionuclide therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0148-2

Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0148-2

Endocrine tumours of the gastrointestinal tract. Peptide receptor radionuclide therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0148-2

90Y-edotreotide for metastatic carcinoid refractory to octreotide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0148-2

Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0148-2

Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0148-2

Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0148-2

Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0148-2

Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0148-2

Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0148-2

O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0148-2

Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0148-2

Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0148-2

Activity of sunitinib in patients with advanced neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0148-2

mTOR-targeted therapy of cancer with rapamycin derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0148-2

An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0148-2

A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0148-2

Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0148-2

Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11864-011-0148-2

Sunitinib malate for the treatment of pancreatic neuroendocrine tumors

21 January 2018

1 reference

12 December 2020

Streptozocin–Doxorubicin, Streptozocin–Fluorouracil, or Chlorozotocin in the Treatment of Advanced Islet-Cell Carcinoma

1 reference

12 December 2020

Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome

1 reference

12 December 2020

First‐line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas

1 reference

12 December 2020

Combination therapy with octreotide and alpha-interferon: effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors

1 reference

12 December 2020

The Role of Interferons in the Management of Carcinoid Tumors

1 reference

12 December 2020

Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine

1 reference

12 December 2020

Liver transplantation for metastatic neuroendocrine tumors

1 reference

12 December 2020

Long-Term Management of the Carcinoid Syndrome Treatment with octreotide alone and in combination with alpha-interferon

1 reference

12 December 2020

Everolimus for advanced pancreatic neuroendocrine tumors.

1 reference

12 December 2020

Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue

1 reference

12 December 2020

Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance.

1 reference

12 December 2020

Differential expression of the PTEN tumor suppressor protein in fetal and adult neuroendocrine tissues and tumors: progressive loss of PTEN expression in poorly differentiated neuroendocrine neoplasms

1 reference

12 December 2020

Neuroendocrine hepatic metastases: does aggressive management improve survival?

1 reference

12 December 2020

10.1007/S11864-011-0148-2

Identifiers

DOI

1 reference

Dimensions Publication ID

31 July 2017

1012261053

0 references

1 reference